Document Detail

Scutellarin alleviates interstitial fibrosis and cardiac dysfunction of infarct rats by inhibiting TGFβ1 expression and activation of p38-MAPK and ERK1/2.
MedLine Citation:
PMID:  20942814     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE: Interstitial fibrosis plays a causal role in the development of heart failure after chronic myocardial infarction (MI), and anti-fibrotic therapy represents a promising strategy to mitigate this pathological process. The purpose of this study was to investigate the effect of long-term administration of scutellarin (Scu) on cardiac interstitial fibrosis of myocardial infarct rats and the underlying mechanisms.
EXPERIMENTAL APPROACH: Scu was administered to rats that were subjected to coronary artery ligation. Eight weeks later, its effects on cardiac fibrosis were assessed by examining cardiac function and histology. The number and collagen content of cultured cardiac fibroblasts exposed to angiotensin II (Ang II) were determined after the administration of Scu in vitro. Protein expression was detected by Western blot technique, and mRNA levels by quantitative reverse transcription-PCR.
KEY RESULTS: The echocardiographic and haemodynamic measurements showed that Scu improved the impaired cardiac function of infarct rats and decreased interstitial fibrosis. Scu inhibited the expression of FN1 and TGFβ1, but produced no effects on inflammatory cytokines (TNFα, IL-1β and IL-6) in the 8 week infarct hearts. Scu inhibited the proliferation and collagen production of cardiac fibroblasts (CFs) and the up-regulation of FN1 and TGFβ1 induced by Ang II. The enhanced phosphorylation of p38-MAPK and ERK1/2 in both infarct cardiac tissue and cultured CFs challenged by Ang II were suppressed by Scu.
CONCLUSIONS AND IMPLICATIONS: Long-term administration of Scu improved the cardiac function of MI rats by inhibiting interstitial fibrosis, and the mechanisms may involve the suppression of pro-fibrotic cytokine TGFβ1 expression and inhibition of p38 MAPK and ERK1/2 phosphorylation.
Zhenwei Pan; Weiming Zhao; Xiangying Zhang; Bing Wang; Jinghao Wang; Xuelin Sun; Xuantong Liu; Shuya Feng; Baofeng Yang; Yanjie Lu
Related Documents :
21844794 - P53 codon 72 polymorphism and coronary artery disease: evidence of association with lef...
17873014 - Delayed expression of cytokines after reperfused myocardial infarction: possible trigge...
16632594 - Hypoxia or nutrient restriction during pregnancy in rats leads to progressive cardiac r...
14985854 - Functional characterization of the human atrial essential myosin light chain (halc-1) i...
16356564 - The relationship between variables of 123-i-metaiodobenzylguanidine cardiac imaging and...
9120684 - Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular e...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  British journal of pharmacology     Volume:  162     ISSN:  1476-5381     ISO Abbreviation:  Br. J. Pharmacol.     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-13     Completed Date:  2011-07-26     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  7502536     Medline TA:  Br J Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  688-700     Citation Subset:  IM    
Copyright Information:
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.
Department of Pharmacology, Harbin Medical University, Harbin, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apigenin / therapeutic use*
Collagen / metabolism
Cytokines / metabolism
Drugs, Chinese Herbal / therapeutic use*
Glucuronates / therapeutic use*
Heart Failure / complications,  drug therapy*,  physiopathology
Hemodynamics / drug effects,  physiology
Mitogen-Activated Protein Kinase 1 / metabolism*
Myocardial Infarction / complications,  drug therapy*,  pathology,  physiopathology
Rats, Wistar
Transforming Growth Factor beta1 / metabolism*
Ventricular Dysfunction, Left / etiology,  physiopathology
Ventricular Remodeling / drug effects
p38 Mitogen-Activated Protein Kinases / metabolism
Reg. No./Substance:
0/Cytokines; 0/Drugs, Chinese Herbal; 0/Glucuronates; 0/Tgfb1 protein, rat; 0/Transforming Growth Factor beta1; 27740-01-8/scutellarin; 520-36-5/Apigenin; 9007-34-5/Collagen; EC protein, human; EC Protein Kinase 1; EC Mitogen-Activated Protein Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Byakangelicin induces cytochrome P450 3A4 expression via transactivation of pregnane X receptors in ...
Next Document:  Critical role of the STAT3 pathway in the cardioprotective efficacy of zoniporide in a model of myoc...